TRADITIONAL POSTER - ismrm

Poster Sessions
2706. MRI Molecular Imaging Monitors Downstream Anti-Angiogenic Effects of MTOR Inhibition
Robert Ross 1 , Jose L. Figueiredo 2 , Peter Waterman 2 , Ralph Weissleder 3 , Alexander R. Guimaraes 4,5
1 Lank Center for Genitourinary Oncology, Dana Farber Cancer Institute, Boston, MA, United States; 2 Center for Systems Biology,
Massachusetts General Hospital, Boston, mA, United States; 3 Center for Systems Biology, Massachusetts General Hospital, Boston,
MA, United States; 4 Radiology, Massachusetts General Hospital/Martinos Center for Biomedical Imaging, Charlestown, MA, United
States; 5 Center for Systems Biology, Massachusetts General Hospital/Martinos Center for Biomedical Imaging, Boston, mA, United
States
Inhibitors of the mammalian target of rapamycin (mTOR) are approved in patients with metastatic renal cell cancer (RCC). Our aim was to evaluate in vivo,
mTOR inhibition on the vascularity of a RCC mouse model using magnetic nanoparticle enhanced MRI and to compare these effects to the established
VEGF inhibitor, sorafenib. There was excellent correlation (R^2 0.95) of MRI measures of vascular volume fraction to histologic microvessel density .
VVF in all treatment arms differed from control (p